JPRN-jRCT2080223118已完成1 期
A phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects with Lymphomas
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Has a pathologically documented non hodgkin's lymphoma (NHL)
- •-Has relapsed from or is refractory to standard treatment or for which no standard treatment is available.
- •-Has an ECOG PS 0-1
- •- >=18 years in the US, >=20 years in Japan
排除标准
- •- Previously had or currently has any of the following diseases: (within 6 months before registration)
- •uncontrolled diabetes, symptomatic congestive heart failure (NYHA classes III-IV), unstable angina, myocardial infarction, arrhythmia requiring treatment
- •-Active tuberculous diseases, herpes simplex, or systemic mycosis requiring treatment
研究者
相似试验
已完成
1 期
Phase 1 study of DS-3201b to evaluate the effect of food (low-fat meal) on the pharmacokinetics in healthy subjectsHealthy subjectsJPRN-jRCT2071200043agao Kiminori28
未知
1 期
Phase 1 Study of BMS-833923 (XL139)CancerJPRN-jRCT2080221644Bristol-Myers K.K.27
已完成
1 期
Phase 1 Study of DS-3201b to Assess the Effects of Multiple Oral Administration of Rifampicin on the Pharmacokinetics of Single Oral Administration of DS-3201b Tablets in Healthy Japanese SubjectsHealthy volunteersJPRN-jRCT2080225242DAIICHI SANKYO Co.,Ltd.20
未知
1 期
Phase 1 study of DS-3201b to assess the effects of itraconazole and fluconazole on the pharmacokinetics of single oral administration of DS-3201b tablets in healthy Japanese subjectsJPRN-jRCT2080223846DAIICHI SANKYO CO., LTD.32
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver CirrhosisAlcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersLiver CirrhosisACTRN12622000392763Surrozen Operating, Inc.40